Press Centre
Press Releases
Phynova hosts a Hepatitis C Morning
Phynova Group plc
("Phynova")
Phynova hosts a Hepatitis C Morning
Phynova Group plc (AIM: PYN), the developer of prescription pharmaceuticals derived from Chinese botanical medicines, yesterday hosted a Hepatitis C Morning in London. With over 170 million patients now infected with the hepatitis C virus worldwide, the event focused on the global healthcare challenge of hepatitis C, the epidemiology of the disease, currently marketed treatments and products in development that could reach the market over the next decade. The latter include Phynova´s PYN17, now in Phase II trials in the USA. PYN17 is the only product currently in clinical development that is specifically aimed at treating the debilitating symptoms and liver inflammation seen in chronic hepatitis C.
The speakers at the event were:
Professor Graham Foster, Professor of Hepatology
Barts and the London, Queen Mary´s School of Medicine & Dentistry
Dr Barbara Domayne-Hayman, Commercial Director, Arrow Therapeutics
Arrow Therapeutics is AstraZeneca´s antiviral hub
Dr John Efthimiou, Chief Medical Officer
Phynova
Copies of the presentations can be obtained from Abchurch Communications.
- Ends -
For further information, please contact:
Phynova Group PLC
+44 (0) 1993 880700
Dr Tony Mills, Director of Business Development
www.phynova.com
Nominated Adviser:
Nabarro Wells & Co. Limited
+44 (0) 20 7710 7400
Marc Cramsie/Harry Stockdale
Broker:
J M Finn & Co. Limited
+44 (0) 20 7628 9688
Sam Smith
Media enquiries:
Abchurch Communications
+44 (0) 20 7398 7700
Peter Laing/Ashley Tapp/Stephanie Cuthbert
Stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com
Notes to Editors:
About Phynova
Phynova is a UK company developing prescription pharmaceuticals derived from Chinese botanical medicines. Phynova is focused on viral and metabolic diseases and cancer. Phynova´s lead product for hepatitis C is now in a Phase IIa trial in the US. Two further products, for fatty liver disease and post-operative ileus, are targeted for entry to the clinic in early 2008 and there are a further three products in preclinical development.
About Hepatitis C and Phynova´s clinical candidate PYN17
Hepatitis C is a liver disease caused by the hepatitis C virus ("HCV"). Hepatitis C is usually transmitted by injections of illicit drugs, or through exposure to contaminated blood or blood products. Symptoms include fatigue, abdominal discomfort or tenderness, muscle and joint pain, nausea and loss of appetite. Symptoms may persist in patients, even after viral clearance following interferon-ribavirin therapy. Chronic hepatitis C can result in cirrhosis of the liver, which can lead to liver failure and other serious complications, and liver cancer.
Hepatitis C affects over 170 million people world wide, including over four million people in the US. Currently available treatments with pegylated interferon and ribavirin are only effective in approximately 50% of patients treated, often with significant associated toxicity and side effects. The market for treatments for hepatitis C is estimated to be US$9 billion by 2010.
Phynova believes that PYN17 is the only drug in clinical development specifically designed to treat the debilitating symptoms of chronic hepatitis C. It is based on a novel formulation of four plant extracts that have a long history of safe and efficacious use in the treatment of liver ailments in Asia and the West.
For further information please visit www.phynova.com;
END
13/07/2007
<< Back | See all current Press releses